1525 Superior Avenue, Suite 200
Newport Beach, CA 92663
Phone (949) 650-0506
Fax (949) 999-8126

Receive our newsletter
  Home  
  Our Team  
  Patient Info  
  Contact Us  

News for Healthier Living

PreludeDx Announces First Independent Validation of AidaBreast(tm), the Only Multi-Omic Test to Predict Locoregional Recurrence Risk and Radiation Therapy Benefit in Early-Stage Invasive Breast Cancer

Prelude Corporation (PreludeDx(r)), a leader in precision diagnostics for early-stage breast cancer, today announced results from the first independent validation of AidaBreast(tm), a novel multi-omic biosignature developed to predict a woman's 10-year risk of locoregional recurrence (LRR) and her individualized benefit from adjuvant radiation therapy (RT) following breast-conserving surgery.

December 10, 2025


December 24 2025

December 23 2025

December 22 2025

December 21 2025

December 20 2025

December 19 2025

December 18 2025

December 17 2025

December 16 2025

December 15 2025

December 14 2025

December 13 2025

December 12 2025

December 11 2025

December 10 2025